|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||

* From the Center for Health Research (Drs. Berglund, Abbey, and Knutson), School of Public Health, Loma Linda University, CA; the Arizona Prevention Center (Dr. Lebowitz), University of Arizona, College of Medicine, Tucson, AZ; and the United States Environmental Protection Agency (Dr. McDonnell), Research Triangle Park, NC.
| Abstract |
|---|
|
|
|---|
Design: An observational survey.
Setting: Several communities in California.
Measurements: Exposures and respiratory history were assessed by standardized questionnaire. PFTs were performed and prediction equations derived.
Results: Significant risk factors for obstruction on PFTs in multiple logistic regression included reported environmental tobacco smoke (ETS) exposure (relative risk [RR] = 1.44), parental CAD or hay fever (RR = 1.47), history of childhood respiratory illness (RR = 2.15), increasing age, and male sex. The number of years of past smoking was of borderline significance (RR = 1.29 for 10 years of smoking; p = 0.06). The prevalence of obstruction on PFTs was 24.9% in those with definite symptomatic CAD, compared with 7.5% in those with no symptoms of CAD. The prevalence of obstruction was 36.0% among those with asthma and 70.6% among those with emphysema. Also, symptomatic CAD correlated with reduction in lung function by analysis of covariance. The mean percent predicted FEV1 adjusted for covariates was 90.6% in persons with definite symptoms of CAD, compared with 97.8% in those without it (p < 0.001).
Conclusions: Age, sex, parental history, childhood respiratory illness, and reported ETS exposures were significant risk factors for obstruction on PFTs. Self-reported respiratory symptoms also correlated significantly with PFTs.
Key Words: chronic airway disease nonsmoking passive smoking pulmonary function respiratory symptoms
| Introduction |
|---|
|
|
|---|
among lifelong nonsmokers in the United States.5 Asthma has a prevalence of 4 to 5% in the United States general population,6 although it may vary by region.7
While smoking is the major recognized risk factor for chronic bronchitis and emphysema, multiple risk factors have some importance for asthma, including air pollution, tobacco smoke exposure, and specific allergens.7 8 9 10 CAD also increases with age in adulthood.6 With the increase in the elderly population and the decrease in smoking in the United States, other risk factors for CAD may become of more importance, particularly in the nonsmoking elderly. Such risk factors may include air pollution, environmental tobacco smoke (ETS) exposure, and genetic predisposition.7 9 10 11 12 13 14
CAD may be assessed with historical information, clinical evaluation including auscultation of lung sounds, and pulmonary function tests (PFTs). Lability in the peak expiratory flow (PEF) measured by the subject at home may be used to indicate bronchial responsiveness, as an alternative to bronchial challenge test.15 16 For large population-based studies, standardized questionnaires that assess history of symptoms and previous diagnoses are often most practical.17 18 19
PFTs, PEF lability, and respiratory symptoms self-reported on the standardized American Thoracic Society (ATS) questions were obtained in a 1993 cohort study of the cumulative effects of decades of exposure to air pollution in California residents.15 20 21 22 This study provides the opportunity to ascertain risk factors for CAD as measured by PFTs in a large community sample of middle-aged and elderly nonsmokers, as well as to correlate CAD as ascertained from the standardized ATS questions with CAD determined from PFTs.
| Materials and Methods |
|---|
|
|
|---|
Two thirds of the participants resided in the South Coast Air Basin, which includes the heavily populated areas of Los Angeles, Orange, Riverside, and San Bernardino counties. The remaining one third resided in the San Diego or San Francisco Air Basins, or were from a 10% geographically ordered random sample of eligible participants from the rest of California.
Selection criteria for this substudy required that subjects have complete air pollution data; live within 20 miles of an air quality monitoring station; have completed mailed questionnaires in 1977, 1987, and 1992; and be less than 80 years old on January 1, 1993. Of 1,870 candidates who met these criteria, 62 refused to participate, 70 were too sick, 11 could not be contacted, 61 were unable to come to a testing site, and 156 were clinic visit no-shows. The remaining 1,510 subjects completed PFTs at the clinic visit in 1993. Data from 1,391 subjects was used, after these additional exclusions: report of current tobacco smoking; missing questionnaire data; incomplete or unacceptable spirometry performance; and disorders other than obstructive lung disease which could affect spirometry, including respiratory infection on the day of testing, congestive heart failure, severe kyphosis or scoliosis, lung cancer, tuberculosis, pneumoconiosis, collapsed lung, or morbid obesity (body mass index of > 45 kg/m2).15 Characteristics of this population are shown in Table 1 .
|
| PFT Methods |
|---|
|
|
|---|
Height, weight, and arm span were measured for use in prediction equations for PFTs. The prediction equations were formulated for a healthy reference subgroup of 565 asymptomatic never smokers.24 Prediction equations were used to obtain percent predicted values for PFTs, including the percent predicted FEV1 (PPFEV1), percent predicted VCmax (PPVCmax) and the percent predicted forced expiratory flow from 25 to 75% of the VC (PPFEF2575).24 For analyses in this study, obstructive disease based on PFTs was defined a priori as either the ratio FEV1/VCmax < 65% or the PPFEV1 < 75%.
Reversible airway obstruction was assessed using bronchodilator response and lability in PEF. The bronchodilator response was obtained as the percent improvement in FEV1 following administration of albuterol.23 This was completed in 1,365 subjects (26 subjects declined or were unable).
Subjects were trained to perform PEF measures in triplicate at home four times daily for 1 week and record the results in a diary. Acceptable peak flow diaries were obtained from 1,223 of 1,391 subjects (requiring at least two acceptable measures per day on at least 3 of the last 5 days of the week). The daily lability was defined as: 100% x (maximum PEF - minimum PEF)/mean PEF
The overall maximum lability in PEF was taken as the average of the two highest daily lability values for the week, after data for the first two days were dropped because of a learning effect.3 15 25
| Respiratory Symptom Algorithms |
|---|
|
|
|---|
Computerized algorithms based on history and respiratory symptoms were used to classify subjects into categories of respiratory symptom complexes.20 For a definite diagnosis of asthma, both reported symptoms of wheezing and history of physician-diagnosed asthma were required. Symptoms related to chronic bronchitis include chronic cough and chronic sputum production, both of which were considered separately. Definite diagnosis of chronic bronchitis of either cough type or sputum type required presence of symptoms on most days for at least 3 months, and also of at least 2 years duration. For a definite diagnosis of emphysema, both reported symptoms of shortness of breath with exertion and history of physician-diagnosed emphysema were required. Comparison is made between these symptom complexes and questions about physician diagnosis of asthma, chronic bronchitis, and emphysema. The term physician diagnosis will be used to mean questionnaire self-report of physician diagnosis.
Analysis of chronic bronchitis was performed only after asthma and emphysema were excluded, as overlap in these diagnoses could otherwise influence the results. Similarly, analysis of emphysema was performed after exclusion of asthma. Analysis of asthma was primarily performed without emphysema or chronic bronchitis excluded, although a sensitivity analysis was done with these exclusions.
| Assessment of Potential Risk Factors and Covariates |
|---|
|
|
|---|
Other potential risk factors and exposures were assessed by questionnaire, and these are listed in Tables 1 and 2 . For reported ETS exposure, a daily average of at least 1 h was required. In addition to any ETS history (dichotomous variable), ETS was also classified more specifically as years living with a smoker as a child, years living with a smoker as an adult, and years working with a smoker.12 An additional dichotomous ETS exposure variable was created to assess any exposure as an adult (combining home and work exposure), and was used in a sensitivity analysis. Reported occupational exposures included the total years of exposure to dust and the number of years of reported exposure to fumes from 1987 to 1993. A history of childhood respiratory illness (dichotomous) included asthma, bronchitis, and pneumonia.
|
| Statistical Methods |
|---|
|
|
|---|
The
2 test was used to compare the
categorization of subjects who had obstruction determined by PFTs with
the categorization of subjects who had CAD determined by self-reported
respiratory symptoms. Analysis of covariance (ANCOVA) was used to
compare PFT results across categories of definite, possible, or no
respiratory disease as determined by algorithms based on self-reported
symptoms, with adjustment made for age, sex, and prior smoking.
Adjusted mean values of PFTs for different categories of respiratory
disease are reported along with significance of differences between
categories of CAD from ANCOVAs.
| Results |
|---|
|
|
|---|
Risk Factors for Obstructive Disease
Multivariate logistic regression was used to evaluate risk factors
for obstructive disease determined by PFTs and to obtain RRs with
confidence intervals (CIs) (Table 2)
. The risk of obstruction detected
by PFTs was significantly positively related to the following factors:
increasing age, male sex, parental CAD or hay fever, childhood
respiratory illness, and any ETS history. Past smoking showed a
borderline significance (RR = 1.29 for 10 years of smoking;
p = 0.06), even though it had been 16 years or more since any subject
had smoked. More detailed analysis of ETS exposure showed significance
only for years living with a smoker as an adult (the other variables,
years working with a smoker and years living with a smoker as a child,
were not significant). Education level failed to show a significant
relationship to risk of PFT-detected obstruction. Neither
PM10(100) nor mean PM10
were significant in models that combined men and women, but in
sex-specific models in men only, these variables did show borderline
significance. Years of occupational exposure to dust and fumes were not
significant. In sex-specific analyses and with exclusion of smokers,
the dichotomous ETS exposure variable decreased to borderline
significance. However, years living with a smoker as an adult remained
significant in both men and women. In men, years of exposure to fumes
at work was significant. In women, parental CAD lost significance.
Subclassification of CAD
There is some overlap in the different types of CAD. Table 3
shows the numbers of subjects having each type of CAD by itself and in
combination with other types of CAD. A total of 209 individuals had
some type of CAD by symptom algorithms, while 222 individuals had some
type of physician-diagnosed CAD. In this study, exclusion of chronic
bronchitis or emphysema for analysis of asthma had no effect on
results, so combined results are presented. However, chronic bronchitis
is presented with asthma and emphysema excluded.
|
Correlation of Symptomatic CAD and PFT-detected Obstruction by
2 Test
Overall, CAD detected by symptom algorithms showed a strong
association with presence of obstruction on PFTs, assessed by the
2 test (Table 4
). Nearly one quarter of those with definite CAD by symptom algorithms
had obstruction detected by PFTs, which is more than three times the
frequency of obstruction in those without CAD.
|
Asthma identified by symptom algorithm also shows a highly significant
relationship to obstruction on PFTs, with a prevalence of obstruction
of 36.0% (Table 4)
. In addition, when examined for the entire group
with the
2 test, chronic sputum production is
significantly related to obstruction on PFTs (Table 4)
. However,
significance is lost when asthma and emphysema are excluded (data not
shown). Chronic cough shows a nonsignificant trend.
Results relating self-report of physician diagnoses to PFTs are not shown in the tables. Among subjects with any physician diagnosis of CAD, the percentage who had PFT-detected obstruction was 23.0%, compared with 8.2% in those who did not report a physician diagnosis of CAD (p < 0.001). For physician-diagnosed asthma, the percentage of subjects with obstruction by PFTs was 29.0%, compared with 8.8% in those without a physician diagnosis of asthma (p < 0.001). For physician-diagnosed emphysema, the percentage of subjects with obstruction by PFTs is 64.0%, compared with 9.6% in those without a physician diagnosis of emphysema (p < 0.001). For physician-diagnosed chronic bronchitis, the percentage of subjects with obstruction by PFTs is 16.5%, compared with 10.0% in those without a physician diagnosis of chronic bronchitis (p = 0.026). However, most of this difference derives from chronic bronchitis subjects who also had asthma or emphysema. When the subjects with concomitant asthma or emphysema were excluded, the percentage of subjects with obstruction on PFTs was similar in those with or without physician-diagnosed chronic bronchitis.
Next, subjects were classified according to whetheror not airflow obstruction was detected in PFTs, and the percentage having definite, possible, or no symptoms of CAD was examined. Among those with airflow obstruction, 35.4% had definite CAD, 20.4% had possible CAD, and 44.2% had no CAD according to the respiratory symptom algorithm. Among those with no airflow obstruction, 12.6% had definite CAD, 22.5% had possible CAD, and 64.9% had no CAD based on the symptom algorithm. Of those with obstructive disease found by PFTs, 34.7% had reported a physician diagnosis of CAD. Among those with no obstruction, 13.7% reported a physician diagnosis of CAD.
ANCOVAs: PFT Results for Different Categories of Respiratory
Disease
The relationships between PFTs and CAD symptom complexes
were also assessed by ANCOVA, using lung function as a continuous
variable. Adjusted mean values of PFT results were obtained from ANCOVA
for different categories of respiratory disease based on symptom
complexes, with adjustments made for age, sex, and past smoking. A
significant test indicates that some differences in the adjusted mean
PFT values exist among the disease severity categories. Overall, CAD
defined by the symptom algorithms was significantly associated with all
the obstructive pulmonary function measures (including
PPFEV1, FEV1/VCmax, and
PPFEF2575), and with the measures of reversible
obstruction (postbronchodilator response and maximum lability in the
PEF), but not with the PPVCmax (Table 5
). The association between asthma indicated by the symptom algorithm and
all the PFTs examined was highly significant (Table 6
), as was physician-diagnosed asthma (Table 7
). Those with definite asthma according to the algorithm had lower
adjusted mean values of obstructive measures and higher PEF lability
and bronchodilator response than those with a reported physician
diagnosis alone. Emphysema identified by the symptom algorithm was
significantly associated with the obstructive measures by ANCOVA, with
the following adjusted mean values for subjects who had definite
emphysema with asthma excluded: PPFEV1 of 81.0%
(p < 0.001), FEV1/VCmax of 65.0%
(p < 0.001), and PPFEF2575 of 68.4%
(p = 0.003). Comparison values for subjects without emphysema are
PPFEV1, 97.5%;
FEV1/VCmax,75.2%; and
PPFEF2575, 98.6%. Emphysema by symptom
algorithm was not significantly associated with the PPVCmax, nor with
changes in the measures of reversible obstruction.
|
|
|
| Discussion |
|---|
|
|
|---|
History of reported ETS exposure averaging at least 1 h daily was associated with obstruction found on PFTs. More detailed analysis of ETS exposure showed that the number of years living with a smoker was significantly related to obstruction found on PFTs. Exposures from work or childhood were not significant. The number of subjects in the AHSMOG Study with current ETS exposure decreased markedly over the study period, and by 1993 few subjects still had current exposure. Greater effects might be seen for more current exposure. Previous analyses of the AHSMOG cohort have shown associations of 1977 prevalence of CAD by symptom algorithms with 10 years or more living with a smoker (RR, 1.07; p < 0.01), and with 10 years or more working with a smoker (RR, 1.10; p < 0.001).29 From 1977 to 1987, these RRs each increased to 1.13 for development of CAD.30 When exposure to ETS in childhood, adult home, and work were combined, a RR of 2.03 (95% CI, 1.45 to 2.77) was found for development of new CAD between 1977 and 1987.12 Asthma with symptoms showed an RR of 1.45 (95% CI, 1.21 to 1.75) for those who had worked with a smoker for 10 years or more.9
There has been a great deal of interest in ETS exposure and possible associated risk of diseases, including CAD, lung cancer, and heart disease.31 32 33 34 Some of the earliest studies to look at lung function and ETS showed little or no effect for the most part,35 36 37 while some of those that showed an effect38 39 had questionable methodology.37 It has been suggested that self-reported duration of exposure to ETS has low reliability, and that this may explain the inability of earlier studies to show a significant dose-response relationship between ETS and lung cancer.40 On the other hand, dichotomous questions on whether or not one was ever exposed to ETS have shown much better reliability.41 Additionally, studies examining the relationships between ETS and symptoms of CAD have shown significant results.9 12 42
More recent studies in adults have been reporting borderline significant relationships between ETS exposure and lung function, with some significant trends of decreased PFTs related to ETS exposure.43 44 45 46 47 The findings on ETS reported here are consistent with others in the literature.48 49
Public health efforts in the United States have attempted to increase awareness of potential effects of ETS, and may be leading to decreases in ETS exposure. This might be expected to contribute to decreased severity of asthma.50 However, the prevalence of asthma has increased since the 1970s, for reasons that are not clear.8 10 Also, depending on how similar the effect of ETS is to the effect of active smoking, cessation of ETS exposure could result in some reduction in age-related decline in lung function for exposed persons.51 Efforts to further document such improvements may be beneficial, particularly if ETS exposure continues to decrease.
Other risk factors studied in this cohort in previous papers included long-term ambient concentrations of air pollutants, examined here using both mean PM10 concentrations and the frequency of PM10 concentrations in excess of 100 µg/m3.13 21 One of these measures was forced into models to adjust for air pollution. Particulate pollution (PM10) may be related especially to chronic cough and chronic sputum.22 Borderline significance of mean PM10 and PM10(100) was seen in men in sex-specific models. These analyses may lack power, as the outcome variable was not continuous. Detailed analyses relating specific air pollutants and lung function in the AHSMOG Study have been conducted recently.52 In these analyses, sex differences were noted. The greatest decrement in lung function associated with PM10(100) was found in male subjects whose parents had CAD or hay fever.52
CAD Symptoms and Obstructive Disease Detected by PFTs
Overall, definite CAD, asthma, and emphysema identified using
algorithms based on self-reported respiratory symptoms all showed a
marked association with PFT findings of obstruction in ANCOVAs. They
all also showed a highly significant relationship with obstruction
found in PFTs, assessed by the
2 test. These
results confirm the use of these algorithms as chronic respiratory
disease indicators for studying associations with ambient air
pollutants and ETS exposures.9
12
13
20
21
29
30
Previous
papers have used the term airway obstructive disease.
However, while asthma and emphysema do involve airway obstruction, the
current analyses did not find chronic bronchitis to be independently
related to airway obstruction.
The association found for self-reported physician diagnosis of CAD with obstruction detected by PFTs was similar to the association for definite CAD by algorithm with obstruction detected by PFTs, although the association was not quite as marked. This is largely because the symptom algorithms for asthma and emphysema are more stringent, requiring both physician diagnosis and current symptoms.
Both a finding of asthma based on symptom algorithm and a self-reported physician diagnosis of asthma showed a very significant association with all PFTs, with a fairly marked decrease in obstructive measures. Measures of reversible obstruction included PEF lability and postbronchodilator response, each of which was markedly elevated for both the algorithm and physician diagnosis of asthma, as expected.
Mild chronic bronchitis may have a reversible component.53 However, when asthma and emphysema were excluded, no significant association was seen between chronic bronchitis and reversible measures of obstruction. Although the small decrement of FEV1/VCmax seen with symptoms of chronic sputum in this study would not appear to be clinically significant, the questions on chronic cough and chronic sputum did contribute to detection of those with obstruction found on PFTs. Other epidemiologic studies have suggested that the use of a direct question about physician-confirmed chronic bronchitis is better correlated with PFTs than is use of the symptoms of chronic cough and chronic phlegm.53 54 In this study, the physician diagnosis of chronic bronchitis was related to decrements in both PPFEV1 and PPVCmax, though not with FEV1/VCmax. It did show more clinical significance than the symptoms in correlation with PFTs, although the decrements found were not large.
Despite the small numbers of people with emphysema by either physician diagnosis or symptom algorithm, reductions in the adjusted mean values for obstructive measures of lung function were readily apparent, and more marked than for either asthma or chronic bronchitis.
Both the symptom algorithms and physician diagnoses labeled some subjects as having obstructive diseases who had little obstruction found on PFTs. With the reversible nature of asthma and variable nature of chronic bronchitis, this is not unexpected. On the other hand, a significant proportion of those with obstructive disease by PFTs were not detected by either the symptom algorithms or report of physician diagnoses. Others have also reported that CAD may often be undiagnosed, particularly in the elderly.2 55 56
Study Limitations
This study has several limitations. The AHSMOG cohort is not a
general population sample, and none of its members currently smoke.
Thus, the risk factors for lung obstruction determined in this cohort
may not be the same as in the general population, especially among
current smokers. Former smokers are included in the AHSMOG Study, but
the prevalence rate of ever smoking is much lower than in the general
population. It had been at least 16 years since any subject had smoked.
Those who were tested were a selected sample of survivors through the study period, and may differ from those in the initial cohort. More healthy subjects may also have been preferentially selected, because previous questionnaires were mailed, while performance of PFTs required travel to a central testing location. Together, these may cause differential loss to follow-up of those with worse PFT results, and thus bias against finding significant risk factors when they exist, similar to the survivor effect 57 or the healthy worker effect.58 Because PFTs were not performed initially, longitudinal decrements of lung function cannot be assessed. Thus, only the prevalence of obstructive disease by PFTs in 1993 can be determined, and not incidence.
This study may have failed to detect significant risk factors for obstruction by PFTs in the multiple logistic regressions due to lack of power, with the relatively small sample size and small number of cases of CAD. For example, PM10(100) was of borderline significance in men. Previous results from this cohort with larger numbers have shown significant results with PM10(100) and symptomatic CAD.13 21 22
Many alternative definitions of obstruction based on PFTs have been used.59 60 The definition used in this paper was selected a priori and is consistent with definitions frequently used in clinical settings; it is more selective than some but more inclusive than others.59 Another method for defining obstruction based on PFTs is to use the ratio of FEV1/FVC less than the fifth percentile of the lower limit of normal in a reference population.60 Such a definition of obstructive disease for this cohort has been created.15 Use of this definition gave a somewhat smaller number with obstructive disease than the definition used in this paper, although in the majority of subjects with obstruction (86 of 116), the definitions overlapped. Using this alternative definition in analysis of variance comparing categories of CAD based on symptom algorithms gave similar results to those presented in this paper. For logistic regressions with this alternative definition, odds ratios were similar to those presented here. However, most variables showed less significance, although prior smoking was slightly more significant.
If this previous definition is revised to additionally include any subjects with PPFEV1 less than 75%, then more subjects will be included. Logistic regressions using this definition of obstruction showed significance for years of prior smoking (RR = 1.34 for 10 years of exposure; p = 0.023) and history of past exposure to ETS as an adult (RR = 1.47 for exposure averaging more than 1 h daily; p = 0.020), and also borderline significance for mean concentration of PM10 exposure (RR = 1.29 for an exposure increment equal to the PM10 interquartile range of 25 µg/m3; p = 0.065).
The use of self-reporting of both symptoms and physician diagnoses for disease assessment is an additional limitation of this study, because subjects may be inconsistent in their recall of symptoms or diagnoses. However, questions on whether subjects had ever had asthma and emphysema showed little inconsistency (less than 1%) when answers from 1992 were compared with 1993 answers. Separating asthma, chronic bronchitis, and emphysema by questionnaire is a weakness, but follows ATS guidelines.20 26 Previously, self-report of diagnosis of asthma has been verified to agree with actual physician diagnosis by abstracting of physician records, performed by Greer et al.9
Other studies have evaluated eosinophilia and IgE levels as risk factors for CAD, and particularly for asthma.54 61 These results are not available on the AHSMOG population, so they cannot be assessed for association with the risk of obstruction. Bronchial challenge tests were not performed. However, questionnaire responses regarding history of wheezing may correlate better with physician assessment of asthma than bronchial challenge tests do.19 62 The PEF index of lability was obtained, and it correlated very well with asthma.15 Nevertheless, a wider battery of physiologic and immunologic tests would have been of great benefit in assessing CAD in this study.25 53
CAD remains an important cause of morbidity and mortality, despite the decline in smoking in this country.63 Large numbers of individuals may have undiagnosed CAD or airway obstruction, which may have few early symptoms. Thus, further study of CAD and airway obstruction and their determinants in nonsmokers is needed.5
| Footnotes |
|---|
Dr. Berglund is now with the National Center for Health
Statistics (NCHS) in Hyattsville, MD. However, this study has not
undergone review by NCHS. ![]()
Supported by EPA Cooperative Agreement no. CR81961902 and the California Air Resources Board Contract no. A933160. Although the research described in this article has been funded by the United States Environmental Protection Agency, it has not been subjected to Agency review, and does not necessarily reflect the view of the Agency. The statements and conclusions in this article are those of the authors and not necessarily those of the California State Air Resources Board.
Correspondence to: David E. Abbey, PhD, Loma Linda University, School of Public Health, CHR, Evans Hall 204, Loma Linda, CA 92350; e-mail: dAbbey@sph.llu.edu
Abbreviations: AHSMOG = Adventist Health Study of Smog; ANCOVA = analysis of covariance; ATS = American Thoracic Society; CAD = chronic airway disease; CI = confidence interval; ETS = environmental tobacco smoke; FEF2575 = forced expiratory flow from 25 to 75% of the vital capacity; PEF = peak expiratory flow; PFT = pulmonary function test; PM10 = particles less than 10 µm in diameter; PM10(100) = number of days per year that PM10 exceeded 100 µg/m3; PPFEF2575 = percent predicted forced expiratory flow from 25 to 75% of the vital capacity; PPFEV1 = percent predicted FEV1; PPVCmax = percent predicted maximum vital capacity; RR = relative risk; VC = vital capacity; VCmax = maximum vital capacity
Received for publication March 10, 1998. Accepted for publication August 11, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
P.-O. Bridevaux, J. Cornuz, J.-M. Gaspoz, B. Burnand, U. Ackermann-Liebrich, C. Schindler, P. Leuenberger, T. Rochat, M. W. Gerbase, and for the SAPALDIA Team Secondhand Smoke and Health-Related Quality of Life in Never Smokers: Results From the SAPALDIA Cohort Study 2 Arch Intern Med, December 10, 2007; 167(22): 2516 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.L. Larsson, H-M. Loit, M. Meren, J. Polluste, A. Magnusson, K. Larsson, and B. Lundback Passive smoking and respiratory symptoms in the FinEsS Study Eur. Respir. J., April 1, 2003; 21(4): 672 - 676. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Radon, K. Busching, J. Heinrich, H.-E. Wichmann, R. A. Jorres, H. Magnussen, and D. Nowak Passive Smoking Exposure* : A Risk Factor for Chronic Bronchitis and Asthma in Adults? Chest, September 1, 2002; 122(3): 1086 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.S. Jaakkola Environmental tobacco smoke and health in the elderly Eur. Respir. J., January 1, 2002; 19(1): 172 - 181. [Abstract] [Full Text] [PDF] |
||||